Searched for: subject%3A%22fibrin%255C%2Bdegradation%255C%2Bproduct%22
(1 - 7 of 7)
document
Hellebrekers, B.W.J. (author), Trimbos-Kemper, T.C.M. (author), Boesten, L. (author), Jansen, F.W. (author), Kolkman, W. (author), Trimbos, J.B. (author), Press, R.R. (author), van Poelgeest, M.I.E. (author), Emeis, S.J. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Objective: To identify predictors of postsurgical adhesion formation in peritoneal fluid and plasma, and assess efficacy and safety of reteplase (recombinant plasminogen activator [r-PA]). Design: Prospective randomized study. Setting: University Medical Center. Patient(s): Twenty-six abdominal myomectomy patients with early second-look...
article 2009
document
Kluft, C. (author), Meijer, P. (author), LaGuardia, K.D. (author), Fisher, A.C. (author), TNO Kwaliteit van Leven (author)
Purpose: The aim of this study was to compare effects of the transdermal contraceptive patch, a desogestrel/ethinyl estradiol (EE)-containing, monophasic combination oral contraceptive (COC) and a levonorgestrel/EE-containing, triphasic COC on hemostasis variables. Study Design: This was a randomized, open-label study of 104 young women who...
article 2008
document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Lugovskoy, E.V. (author), Kolesnikova, I.N. (author), Gritsenko, P.G. (author), Zolotareva, E.N. (author), Gaffney, P. (author), Nieuwenhuizen, W. (author), Komisarenko, S.V. (author), TNO Preventie en Gezondheid (author)
Monoclonal antibody (mAb) III-3b binds D-dimer with Kd = 1.4 × 10-10 M without cross-reaction with fibrin(ogen). The epitope for this mAb is in Bβ134-190, presumably in Bβ155-160. The latter site is buried in the coiled coil structure of fibrin(ogen) but it is exposed as a neoantigenic determinant in D-dimer upon plasmic lysis of fibrin. mAb III...
article 2002
document
TNO Preventie en Gezondheid (author), Meijers, J.C.M. (author), Oudijk, E.J.D. (author), Mosnier, L.O. (author), Bos, R. (author), Bouma, B.N. (author), Nieuwenhuis, H.K. (author), Fijnheer, R. (author)
Acute promyelocytic leukaemia (APL) is a disease that is distinguished from other leukaemias by the high potential for early haemorrhagic death. Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between...
article 2000
document
Haverkate, F. (author), Koopman, J. (author), Koppert, P. (author), Nieuwenhuizen, W. (author), Gaubius Institute, Health Research Division TNO, 2313 AD Leiden, Netherlands (author)
article 1985
document
Verheijen, J.H. (author), Nieuwenhuizen, W. (author), Wijngaards, G. (author), Gaubius instituut TNO (author)
Tissue activator-mediated plasminogen activation is potentiated both by fibrin and by some soluble fibrin(ogen) fragments. The potentiating effect of the different fragments decreases in the order fibrin monomer > D-dimer > Y > D EGTA > Dcate > X. Fibrinogen and the fragments Ecate, E EGTA and E fibrin have almost no effect. The existence of a...
article 1982
Searched for: subject%3A%22fibrin%255C%2Bdegradation%255C%2Bproduct%22
(1 - 7 of 7)